Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.

Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2

The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes

Inclusion Criteria:

• Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea.
• Age: 25-75 years
• BMI>25 kg/m2
• HbA1c 6,0-10 %

Exclusion Criteria:

• Current treatment with insulin or Dipeptidyl peptidase IV inhibitor.
• Haemoglobin < 6.5 mmol/l
• Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.
• Allergy towards victoza ® (liraglutide ), Dipyridamol, Nitroglycerin or rescue medicine: Theophyllin
• Pregnancy
• Severe asthma
• Active cancer
• Severe co-morbidity with limited life-expectancy
• Estimated glomerular filtration rate (eGFR) <60 (measured at baseline)
• Severe hepatic co-morbidity
• Chronic alcohol abuse
• Heart failure with a left ventricular ejection fraction </= 45%
• Atrial fibrillation
• Chronic or previous acute pancreatitis
• Inflammatory bowel disease.